Cash on Hand for Regeneron Pharmaceuticals (REGN)
According to Regeneron Pharmaceuticals's latest reported financial statements, the company's latest reported cash and short-term investments is $8.61B USD. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for a net cash/debt picture and with total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingCash on HandSwitch metric
Latest period
$8.61B
YoY change
-4.5%
5Y CAGR
+19.1%
Peak year (2023)
$10.84B
Latest annual
$8.61B
Cash on Hand history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Cash on Hand history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
| Fiscal year | Period ended | Reported | Cash on Hand | YoY |
|---|---|---|---|---|
| 2025 | $8.61B | -4.5% | ||
| 2024 | $9.01B | -16.9% | ||
| 2023 | $10.84B | +40.1% | ||
| 2022 | $7.74B | +36.0% | ||
| 2021 | $5.69B | +58.8% | ||
| 2020 | $3.59B | +11.6% | ||
| 2019 | $3.21B | +14.4% | ||
| 2018 | $2.81B | +99.4% | ||
| 2017 | $1.41B | +35.7% | ||
| 2016 | $1.04B | -0.6% | ||
| 2015 | $1.05B | +16.1% | ||
| 2014 | $900.48M | +29.8% | ||
| 2013 | $693.98M | +125.3% | ||
| 2012 | $308.10M | -41.5% | ||
| 2011 | $526.94M | +111.3% | ||
| 2010 | $249.37M | -26.9% | ||
| 2009 | $341.33M | -28.1% | ||
| 2008 | $474.75M | -38.1% | ||
| 2007 | $766.46M | +66.9% | ||
| 2006 | $459.28M | +53.8% | ||
| 2005 | $298.55M | +0.9% | ||
| 2004 | $295.98M | +0.8% | ||
| 2003 | $293.77M | +11.2% | ||
| 2002 | $264.27M | -31.4% | ||
| 2001 | $385.08M | +227.4% | ||
| 2000 | $117.61M | +77.7% | ||
| 1999 | $66.20M | +234.3% | ||
| 1998 | $19.80M | -31.5% | ||
| 1997 | $28.90M | -16.2% | ||
| 1996 | $34.50M | +5.5% | ||
| 1995 | $32.70M | +38.6% | ||
| 1994 | $23.60M | +88.8% | ||
| 1993 | $12.50M | -23.8% | ||
| 1992 | $16.40M | -37.4% | ||
| 1991 | $26.20M | +20.2% | ||
| 1990 | $21.80M | — |
Cash on Hand values are taken from Regeneron Pharmaceuticals's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
As of the 2025 fiscal year, Regeneron Pharmaceuticals (REGN) reported cash and short-term investments of $8.61B – edged down 4.5% year-over-year.
Regeneron Pharmaceuticals cash and short-term investments compound annual growth for the 2020–2025 (5 years) window is +19.1%, with the latest reading among the more recent periods of the dataset.
Regeneron Pharmaceuticals cash and short-term investments peaked at $10.84B in 2023; the latest annual figure is $8.61B in 2025 (20.7% below peak).
$10.84B stands as the all-time-high annual cash and short-term investments, posted in 2023, against a low of $12.50M during 1993.
Regeneron Pharmaceuticals (REGN) sits 6th of 8 Healthcare peers we track on this metric, against a peer median of $11.85B.
Regeneron Pharmaceuticals Cash on Hand by Year
Regeneron Pharmaceuticals Cash on Hand 2025: $8.61B
Regeneron Pharmaceuticals cash and short-term investments in 2025 was $8.61B, edged down 4.5% below 2024.
Regeneron Pharmaceuticals Cash on Hand 2024: $9.01B
Regeneron Pharmaceuticals cash and short-term investments in 2024 was $9.01B, declined 16.9% below 2023.
Regeneron Pharmaceuticals Cash on Hand 2023: $10.84B
Regeneron Pharmaceuticals cash and short-term investments in 2023 was $10.84B, surged 40.1% from 2022. This figure represents the highest annual value in the available history.
Regeneron Pharmaceuticals Cash on Hand 2022: $7.74B
Regeneron Pharmaceuticals cash and short-term investments in 2022 was $7.74B, surged 36.0% from 2021.
Regeneron Pharmaceuticals Cash on Hand 2021: $5.69B
Regeneron Pharmaceuticals cash and short-term investments in 2021 was $5.69B.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers — Cash on Hand
Companies in the same sector as Regeneron Pharmaceuticals, ranked by their latest cash and short-term investments.
| Company | Cash on Hand | Sector |
|---|---|---|
| UnitedHealth Group Incorporated (UNH) | $28.12B | Healthcare |
| Novo Nordisk A/S (NVO) | $26.96B | Healthcare |
| Johnson & Johnson (JNJ) | $20.10B | Healthcare |
| Merck & Co., Inc. (MRK) | $14.56B | Healthcare |
| Amgen Inc. (AMGN) | $9.13B | Healthcare |
| Eli Lilly and Company (LLY) | $7.27B | Healthcare |
| AstraZeneca PLC (AZN) | $5.74B | Healthcare |
| AbbVie Inc. (ABBV) | $5.26B | Healthcare |
Frequently asked questions
What is Regeneron Pharmaceuticals's cash and short-term investments?
- Latest reported cash and short-term investments for Regeneron Pharmaceuticals (REGN) is $8.61B (period ending December 31, 2025).
How has Regeneron Pharmaceuticals cash and short-term investments changed year-over-year?
- Regeneron Pharmaceuticals (REGN) cash and short-term investments changed -4.5% year-over-year on the latest annual filing.
What is the long-term growth rate of Regeneron Pharmaceuticals cash and short-term investments?
- Regeneron Pharmaceuticals (REGN) cash and short-term investments compound annual growth rate is +19.1% over the most recent 5 years available.
When did Regeneron Pharmaceuticals cash and short-term investments hit its highest annual value?
- Regeneron Pharmaceuticals cash and short-term investments reached its highest annual value of $10.84B in 2023.
What was Regeneron Pharmaceuticals cash and short-term investments in 2024?
- Regeneron Pharmaceuticals (REGN) cash and short-term investments in 2024 was $9.01B.
What was Regeneron Pharmaceuticals cash and short-term investments in 2025?
- Regeneron Pharmaceuticals (REGN) cash and short-term investments in 2025 was $8.61B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
REGN Overview
Company profile, financial tools, and key metrics
REGN Revenue Counter
Earns $454.81 every second. See per minute, hour, and day.
REGN Earnings Counter
Earns $142.85 per second net profit. See per minute, hour, and day.
REGN Economic Scale
Exceeds Rwanda's GDP. Compare with world economies.
REGN What If Invested
What if you had invested $1,000? See historical returns from any date.
REGN How It Makes Money
Discover visual breakdown of $14.34B in revenue — where it comes from and where it goes.
REGN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
REGN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
REGN Daily Price Character
Explosive · 47.1% historical win rate (green days). Streaks & record days.
REGN Buybacks
4.33% TTM buyback yield. Shareholder yield & SBC comparison.
REGN Dividend Profile
Yield: 0.52%. See full history.
REGN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
REGN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.